Beam Therapeutics Inc.
About Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $139.7M
- Net income
- -$80.0M
- Total assets
- $1.5B
- Market cap
- $3.0B
- Operating margin
- -274.6%
- Net margin
- -57.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $139.7M
- Operating expenses
- $523.4M
- Operating income
- -$383.7M
- Income tax
- $0
- Net income
- -$80.0M
- EPS (basic)
- $-0.81
- EPS (diluted)
- $-0.81
Balance sheet
- Total assets
- $1.5B
- Current assets
- $1.3B
- Total liabilities
- $242.8M
- Current liabilities
- $96.9M
- Shareholders’ equity
- $1.2B
Cash flow
- Operating cash flow
- -$345.1M
- Investing cash flow
- -$121.4M
- Financing cash flow
- $478.0M
- Net cash flow
- $11.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $3.0B
- EPS (diluted)
- $-0.81
- Dividend yield
- 3.02%
- Shares outstanding
- 101.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 6, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $80.0M in FY2025.
- Revenue grew 170% from FY2021 to FY2025.
- Trading 16% below its 52-week high.
- Pays a dividend yielding about 3.02% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Beam Therapeutics Inc..
Write a review
News about Beam Therapeutics Inc.
News & sentiment via Polygon.io
